Fused Aromatic Heterocycles
- High-purity Fused Aromatic Heterocycles
- Extensive range of Fused Aromatic Heterocycles
- Ideal for drug discovery applications and organic synthesis
- Fast delivery and expert support
Fused Aromatic Heterocycles compounds are essential building blocks in pharmaceutical research. Our carefully curated selection offers diverse structures for SAR studies and lead optimization, ensuring quality and reliability for your projects.
Browse by Subcategory
Filters
Filters
Availability
Price (EUR)
€10
€3110
Medicinal Properties
sLogP Lipophilicity
-12.7
11.1
Molecular Weight (g/mol)
g/mol0
g/mol1460
HBD (H-Bond Donors)
0
14
HBA (H-Bond Acceptors)
0
34
Sort by:
Active filters:
Halides, Fused Aromatic Heterocycles
AS292115
6-Bromo-imidazo[1,2-b]pyridazine-3-carbonitrile 97%
CAS:
1592865-99-0
Size:
1 g
Formula:
C7H3BrN4
MW:
223.02
MDL:
MFCD31557186
Price from
€640.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.36348
HBD:
0
HBA:
4
6-Bromo-imidazo[1,5-a]pyridine-1-carboxylic acid 97%
CAS:
1427405-61-5
Size:
250 mg
Formula:
C8H5BrN2O2
MW:
241.04
MDL:
MFCD23708380
Price from
€942.00
per 250MG
Drug-likeness properties
Drug-likeness:
sLogP:
1.795
HBD:
1
HBA:
3
6-Bromo-imidazo[1,5-a]pyridine-3-carboxylic acid 95%
CAS:
1159827-21-0
Size:
250 mg
Formula:
C8H5BrN2O2
MW:
241.04
MDL:
MFCD12401350
Price from
€380.00
per 250MG
Drug-likeness properties
Drug-likeness:
sLogP:
1.795
HBD:
1
HBA:
3
6-Bromo-indolizine-3-carboxylic acid 95%
CAS:
1823882-04-7
Size:
100 mg
Formula:
C9H6BrNO2
MW:
238.96
MDL:
MFCD27937066
Price from
€1,115.00
per 100MG
Drug-likeness properties
Drug-likeness:
sLogP:
2.4
HBD:
1
HBA:
2
Halides, Fused Aromatic Heterocycles
AS126438
6-Bromo-indolizine-3-carboxylic acid ethyl ester 95%
CAS:
1823869-48-2
Size:
100 mg
Formula:
C11H10BrNO2
MW:
266.99
MDL:
MFCD27989335
Price from
€970.00
per 100MG
Drug-likeness properties
Drug-likeness:
sLogP:
2.8785
HBD:
0
HBA:
3
Halides, Fused Aromatic Heterocycles
AS133225
6-Bromo-N-Boc-3H-imidazo[4,5-b]pyridin-2-amine 95%
CAS:
-
Size:
1 g
Formula:
C11H13BrN4O2
MW:
313.15
MDL:
MFCD32068446
Price from
€844.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
3.0674
HBD:
2
HBA:
4
6-Bromo-pyrazolo[1,5-a]pyridine-3-carboxylic acid 97%
CAS:
1211596-19-8
Size:
1 g
Formula:
C8H5BrN2O2
MW:
241.04
MDL:
MFCD11109787
Price from
€125.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.795
HBD:
1
HBA:
3
6-Bromo-pyrazolo[1,5-a]pyrimidine-3-carbaldehyde 95%
CAS:
1263060-72-5
Size:
1 g
Formula:
C7H4BrN3O
MW:
226.03
MDL:
MFCD18839109
Price from
€567.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.3043
HBD:
0
HBA:
4
6-Bromo-pyrido[2,3-d]pyrimidin-4-ylamine 95%
CAS:
1121633-45-1
Size:
1 g
Formula:
C7H5BrN4
MW:
225.04
MDL:
MFCD11875768
Price from
€842.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.3695
HBD:
1
HBA:
4
6-Bromo-pyrrolo[1,2-a]pyrazine-3-carboxylic acid 97%
CAS:
749846-42-2
Size:
1 g
Formula:
C8H5BrN2O2
MW:
241.04
MDL:
MFCD22201143
Price from
€1,856.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.795
HBD:
1
HBA:
3
Halides, Fused Aromatic Heterocycles
AS120269-B
6-Bromo-pyrrolo[1,2-a]pyrazine-3-carboxylic acid ethyl ester 96%
CAS:
588720-62-1
Size:
250 mg
Formula:
C10H9BrN2O2
MW:
269.09
MDL:
MFCD09953513
Price from
€714.00
per 250MG
Drug-likeness properties
Drug-likeness:
sLogP:
2.2735
HBD:
0
HBA:
4
6-Bromo[1,2,4]triazolo[1,5-a]pyrazine 97%
CAS:
1233026-51-1
Size:
1 g
Formula:
C5H3BrN4
MW:
199.01
MDL:
MFCD12923113
Price from
€85.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
0.8868
HBD:
0
HBA:
4
6-Bromo[1,2,4]triazolo[1,5-a]pyridin-2-amine 97%
CAS:
947248-68-2
Size:
1 g
Formula:
C6H5BrN4
MW:
213.03
MDL:
MFCD11656619
Price from
€24.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.074
HBD:
1
HBA:
4
6-Bromo[1,2,4]triazolo[1,5-a]pyridine 97%
CAS:
356560-80-0
Size:
1 g
Formula:
C6H4BrN3
MW:
198.02
MDL:
MFCD08689534
Price from
€25.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.4918
HBD:
0
HBA:
3
6-Bromo[1,2,4]triazolo[1,5-a]pyrimidine 97%
CAS:
89167-24-8
Size:
1 g
Formula:
C5H3BrN4
MW:
199.01
MDL:
MFCD09971401
Price from
€96.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
0.8868
HBD:
0
HBA:
4
6-Bromo[1,2,4]triazolo[4,3-a]pyridine-3-thiol 97%
CAS:
1093092-64-8
Size:
1 g
Formula:
C6H4BrN3S
MW:
230.09
MDL:
MFCD11504977
Price from
€306.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.7805
HBD:
1
HBA:
4
Halides, Fused Aromatic Heterocycles
AS217698
6-Bromo[1,2,4]triazolo[4,3-a]pyrimidine 98%
CAS:
1019023-12-1
Size:
250 mg
Formula:
C5H3BrN4
MW:
199.01
MDL:
MFCD09994391
Price from
€142.00
per 250MG
Drug-likeness properties
Drug-likeness:
sLogP:
0.8868
HBD:
0
HBA:
4
6-Bromoimidazo[1,2-a]pyrazin-2-amine 97%
CAS:
1103861-38-6
Size:
250 mg
Formula:
C6H5BrN4
MW:
213.03
MDL:
MFCD19441495
Price from
€132.00
per 250MG
Drug-likeness properties
Drug-likeness:
sLogP:
1.074
HBD:
1
HBA:
4
6-Bromoimidazo[1,2-a]pyrazin-8-amine 95%
CAS:
117718-84-0
Size:
1 g
Formula:
C6H5BrN4
MW:
213.03
MDL:
MFCD00874115
Price from
€98.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.074
HBD:
1
HBA:
4
6-Bromoimidazo[1,2-a]pyrazine 97%
CAS:
912773-24-1
Size:
1 g
Formula:
C6H4BrN3
MW:
198.02
MDL:
MFCD09750036
Price from
€25.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.4918
HBD:
0
HBA:
3
6-Bromoimidazo[1,2-a]pyrazine-2-carboxylic acid 95%
CAS:
1000018-56-3
Size:
1 g
Formula:
C7H4BrN3O2
MW:
242.03
MDL:
MFCD09414724
Price from
€79.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.19
HBD:
1
HBA:
4
6-Bromoimidazo[1,2-a]pyrazine-3-carboxylic acid 95%
CAS:
1404480-51-8
Size:
250 mg
Formula:
C7H4BrN3O2
MW:
242.03
MDL:
MFCD27635053
Price from
€160.00
per 250MG
Drug-likeness properties
Drug-likeness:
sLogP:
1.19
HBD:
1
HBA:
4
6-Bromoimidazo[1,2-a]pyridin-8-amine 95%
CAS:
676371-00-9
Size:
1 g
Formula:
C7H6BrN3
MW:
212.05
MDL:
MFCD08273920
Price from
€72.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
1.679
HBD:
1
HBA:
3
6-Bromoimidazo[1,2-a]pyridin-8-ol dihydrochloride 97%
CAS:
1379358-48-1
Size:
1 g
Formula:
C7H7BrCl2N2O
MW:
285.95
MDL:
MFCD28142911
Price from
€179.00
per 1G
Drug-likeness properties
Drug-likeness:
sLogP:
2.646
HBD:
1
HBA:
3
Understanding Fused Aromatic Heterocycles in Modern Chemistry
Explore the critical role of Fused Aromatic Heterocycles in pharmaceutical development, medicinal chemistry research and organic chemistry.
Precision Chemistry
Advanced synthesis techniques for superior quality compounds
Great Molecules for Chemical Diversity
Our catalogue of building blocks contains a diverse range of highly functionalised and decorated compounds. The 20 years of experience in supplying cutting-edge building blocks have given us the expertise to bring you the most exciting chemical motifs, adding chemical diversity to your projects.
Our diverse catalogue is tailored for medicinal chemistry, small molecule drug discovery and organic synthesis. Our unique range of Fused Aromatic Heterocycles adds value to any research project.
We constantly add to our catalogue; the latest additions include a range of new Fused Aromatic Heterocycles. We continue to bring you the latest and most exciting chemical compounds.
Quality Assurance
Every Fused Aromatic Heterocycles product in our portfolio undergoes rigorous quality control testing. Our building blocks are supplied with the highest purity standards. We provide complete analytical characterisation, including:
- ¹H and ¹³C NMR spectroscopy for structural verification
- HPLC chromatograms confirming purity levels
- Certificate of Analysis available.
- Standard purity of 95%
- Specific purity available upon request.
Diverse Applications
From oncology to neuroscience, enabling next-generation therapeutics
Wide range of Fused Aromatic Heterocycles
in our catalogue
Found in over 60% of FDA-approved drugs
95% of compounds
available from stock
Fused Aromatic Heterocycles products in our portfolio
Fused aromatic heterocycles are some of the most heavily used pharmacophores in drug discovery, among them indole, benzimidazole, quinoline, purine, and benzothiophene, and it occupies a privileged position in medicinal chemistry because ring fusion combines the favourable binding properties of individual aromatic rings with an extended, locked geometry that single rings cannot achieve. The fusion of two rings removes a degree of conformational freedom relative to two separately linked aromatic systems, fixing the relative orientation of substituents projecting from each ring and allowing more precise complementarity with extended or multi-subsite binding pockets, particularly in kinase ATP sites, GPCR orthosteric pockets, and nucleic acid-binding grooves. The larger, continuous π-system created by fusion strengthens π-stacking and intercalative interactions relative to a monocyclic aromatic ring, while the heteroatom incorporated into the ring system contributes hydrogen bond donor or acceptor capacity at a position precisely defined by the fused architecture, a feature exploited extensively in the design of hinge-binding kinase inhibitor cores. Many fused heterocyclic scaffolds also have a basis in essential biological building blocks, with purine and pyrimidine ring fusions found throughout nucleotide and nucleic acid chemistry, lending innate recognisability to enzymes that process natural substrates.
Synthetic accessibility has expanded considerably for many fused heterocyclic systems through transition metal-catalysed cyclisation, C–H activation and annulation methodologies, and multicomponent reactions, allowing rapid generation of substituted analogues for structure-activity relationship exploration across multiple positions on both fused rings simultaneously. Fused heterocycles provide the flexibility to modulate the pharmacological profile and efficacy of new drug molecules, and the wide range of possibilities to fuse available heterocycles, combined with accessibility to advanced synthetic methodologies, has established these systems as privileged scaffolds in drug development. A structural consideration in fused aromatic heterocycle design is that the extended planar surface area, while beneficial for target engagement, can increase the risk of poor aqueous solubility and non-specific binding relative to smaller, single-ring systems, making careful balance of polar substituents and overall molecular size an important part of lead optimisation in this structural class.
Two FDA-approved drugs illustrate the broad pharmacological reach of fused aromatic heterocycles. Omeprazole (Prilosec, AstraZeneca), the first proton pump inhibitor approved by the FDA in 1989, is built around a benzimidazole core, a fused bicyclic system formed from a benzene ring fused to an imidazole, connected via a sulfinyl linker to a substituted pyridine; in the acidic environment of the parietal cell canaliculus, the protonated benzimidazole nitrogen drives an intramolecular cyclisation to a reactive sulphenamide that forms a covalent bond with cysteine residues of the gastric H+/K+-ATPase, irreversibly inhibiting acid secretion. Osimertinib (Tagrisso, AstraZeneca), an irreversible third-generation EGFR tyrosine kinase inhibitor granted accelerated FDA approval in 2015 as the first targeted therapy for EGFR T790M resistance mutation-positive non-small cell lung cancer, contains an indole-fused bicyclic ring system connected to a pyrimidine core, with structural optimisation of these two fused heterocyclic components having been central to achieving high selectivity for the double-mutant kinase over wild-type EGFR.
Our range of fused aromatic heterocycle building blocks features novel substitutions and the incorporation of synthetically tractable functional groups such as boronic acids and esters, amines, carboxylic acids, ketones, hydroxyls and halogens to enable expedient synthetic strategies. The full range can be found using the substructure feature of our Search tools.
Frequently Asked Questions
Common questions about our Fused Aromatic Heterocycles products.
Fused aromatic heterocycles are ring systems where two or more aromatic rings share a common bond, and at least one ring contains a heteroatom such as nitrogen, oxygen or sulphur. Examples include indole, benzimidazole, quinoline, purine and benzothiophene. This fusion locks the rings into a fixed, extended geometry that a single ring cannot achieve on its own. That structural rigidity is a big part of why these scaffolds show up so often in drug design.
They combine the binding strengths of individual aromatic rings with a fixed, extended shape that fits deep or multi-part binding pockets. Ring fusion removes a degree of conformational freedom, so substituents on each ring stay in a set position relative to each other. This allows more precise fit with sites like kinase ATP pockets, GPCR orthosteric pockets and nucleic acid grooves. Many of these scaffolds also mirror natural building blocks, such as purines and pyrimidines found in nucleotides, which helps them get recognised by enzymes that process natural substrates.
Ring fusion creates a larger, continuous pi-system, which strengthens pi-stacking and intercalative interactions beyond what a single ring can offer. The heteroatom built into the fused system also provides a hydrogen bond donor or acceptor at a precise, fixed position. This combination is used heavily in the design of hinge-binding kinase inhibitor cores. The result is stronger, more specific interactions with the target site.
Yes, synthetic accessibility has grown substantially through transition metal-catalysed cyclisation, C-H activation, annulation methods and multicomponent reactions. These techniques let chemists generate substituted analogues quickly, and they can modify multiple positions on both fused rings at once. This speeds up structure-activity relationship studies during drug development. It is one of the reasons these scaffolds remain a first choice for lead optimisation.
Omeprazole, sold as Prilosec, was the first proton pump inhibitor approved by the FDA, in 1989, and it is built around a benzimidazole core. This benzimidazole is a fused bicyclic system made from a benzene ring joined to an imidazole ring, connected through a sulfinyl linker to a substituted pyridine. In the acidic environment of the stomach's parietal cells, the protonated benzimidazole nitrogen triggers a reaction that forms a covalent bond with the gastric acid pump, shutting down acid secretion. This mechanism depends directly on the fused ring structure.
Osimertinib, sold as Tagrisso, is a third-generation EGFR inhibitor that received accelerated FDA approval in 2015 for a specific type of drug-resistant lung cancer. It contains an indole-fused bicyclic ring system connected to a pyrimidine core. Fine-tuning these two fused heterocyclic parts was central to making the drug highly selective for the resistant, double-mutant form of EGFR over the normal version. This shows how fused ring design can directly drive drug selectivity.
Common additions include boronic acids and esters, amines, carboxylic acids, ketones, hydroxyls and halogens. These groups are chosen because they are synthetically tractable, meaning they support fast and reliable follow-up chemistry. Adding them to a fused heterocycle core gives chemists more options for building out a molecule during drug development. This makes the core scaffold more useful across different synthetic routes.
Still have questions?
Our technical support team is here to help with any inquiries about our Fused Aromatic Heterocycles products.